The yESTRO mentoring program and a report from a mentee

The ESTRO vision statement for 2030 is “Radiation Oncology. Optimal Health for All, Together”. It is becoming increasingly clear that optimal health for all should include the health of caregivers, too. This is exemplified by the high level of burnout amongst radiation oncology professionals across the disciplines, as published recently by Franco et al. (1) Sadly, the COVID pandemic has had a negative impact on mental health of these professionals. (2) The young ESTRO committee (yESTRO) has aligned its activities to the ESTRO vision by setting up an ESTRO mentoring program in order to increase professional well-being for its young members. Mentorship benefits both mentor and the mentee. A review on mentorship in the medical field reported it to have an ‘important influence on personal development, career guidance, career choice, and research productivity, including publication and grant success’. (3) For mentors the benefits lie in enhancement of knowledge, leadership skills, educational skills and increased job satisfaction. With the yESTRO mentoring pilot program, yESTRO specifically aims to satisfy unmet needs for mentorship among young ESTRO members. Fifteen young members were selected as mentees based on their curriculum and personal motivation. The program had its official kickoff at ESTRO 2021 in Madrid with an onsite and an online speed dating session between mentors and mentees. Matches were made and mentor-mentee couples committed to meet at least every three months for the duration of one year. We will present the mid-term evaluation of the pilot at ESTRO 2022. The final evaluation takes place one year after the program started, after which it will be decided whether the program will continue. Yet the ambition of yESTRO is larger. This session will also provide practical advice for those considering to set up a mentoring program at their own institute. Or those seeking a mentor. In this ambition, we will be helped by the experiences shared by Daniel Portik, one of the mentees in the yESTRO mentoring program pilot.

Screening of COVID-19 disease based on chest CT and PCR for cancer patients undergoing radiotherapy in a French coronavirus hotspot

Background: The coronavirus disease (COVID-19) pandemic has caused 180,000 confirmed cases in France with more than 28, 000 deaths as of May 19. A large part of COVID-19 patients seem asymptomatic and cancer patients may be more vulnerable. We evaluated a screening strategy combining chest computed tomography (CT) and PCR for patients treated with radiotherapy (RT). Methods: A screening strategy was organized from March 18, in our RT department. An inspiratory breath hold chest acquisition was proposed during the CT simulation for RT. Images was reviewed by a radiologist according to the CO-RADS classification. A nasal swab with a polymerase chain reaction (PCR) assay was proposed by the radiation oncologist in case of evocative imaging or clinical context. For patients who were already undergoing RT at this time, a PCR was proposed in case of evocative symptoms and before concomitant chemotherapy. Results: From March 18 to May 1, 2020, 507 CT simulation were performed for 449 patients, including 445 chest acquisition. 237 of the chest CT (53%) showed lung abnormalities, of which 34 (8%) were COVID-19 compatible (CO-RADS ≥ 3). 102 patients were tested by PCR after the chest CT. 24 of the 449 (5.3%) patients were considered as COVID-19 patients: 19 had positive PCR, and five were considered positive on the basis of imaging despite PCR-negative PCR. Four of the patients (17%) were diagnosed during RT: 3 on routine screening before chemoradiotherapy, and one on symptoms. Four patients needed several PCR for the diagnosis of COVID-19 with six confirmed false negative PCR (Sensitivity (Se)= 76 % (19/25)). Three PCR positive patients had no evocative lung images (Se = 84%). During this period, an additional 169 patients whose CT simulation was prior to March 18, were also undergoing RT. Among them, six patients (3.6%) were diagnosed with COVID-19 by PCR during RT, performed for symptoms in 4 cases and on screening for the other 2. Of the 30 COVID-19 patients, only 8 (27%) had symptoms at the time of diagnosis. Twelve patients (40%) reported no symptoms and benefited from screening. Conclusions: This study confirms the high proportion of asymptomatic patients with COVID-19 and suggests the value of screening by CT and PCR during COVID-19 pandemics. Legal entity responsible for the study: The authors. Funding: Has not received any funding. Disclosure: R. Sun: Travel/Accommodation/Expenses: AstraZeneca. E. Deutsch: Advisory/Consultancy: Roche, BMS, Boehringer, Astrazeneca, Lilly Amgen and Merck-Serono. All other authors have declared no conflicts of interest.